7th Joint AFNET/EHRA Consensus Conference

Management of patients with AF: New therapies and special populations

14th - 16th March 2019, Lisbon, Portugal

Scientific committee

Hein Heidbüchel (Antwerp, Belgium)
Gerhard Hindricks (Leipzig, Germany)
Paulus Kirchhof (Birmingham, UK)
Ulrich Schotten (Maastricht, Netherlands)

Preliminary report
Press release

On the importance of the conference (Paulus Kirchhof):

Atrial fibrillation (AF) remains a major health challenge. Despite the progress made in the last decade, AF still contributes to mortality and morbidity and to cognitive decline and dementia. Exciting new insights into AF management led to new approaches to treatment. These novel concepts require discussion.

For this purpose, more than 65 specialists in atrial fibrillation – invited scientists from 11 European countries, Canada and the USA, as well as industry representatives from seven companies – met in Lisbon, Portugal, to discuss new strategies for the management of patients with atrial fibrillation.


The two-day expert meeting started with presentations in a plenary session. Thereafter, participants split into eight workshop groups to work on specific questions. The results of these workshops were summarized and discussed in additional plenaries to achieve a consensus. This will be published in a consensus report.


Picture of the participants (Photo: ESC)

Plenary Sessions:

For watching the talks please click on the titles below.

 CATCH ME Session: Stratification of patients with AF

CHAIRS: Hein Heidbüchel und Paulus Kirchhof (Welcome and  Introduction)


Rhythm control therapy - an update

CHAIRS: Ulrich Schotten und Christophe Leclercq


Stroke prevention I

CHAIRS: José Merino und Andreas Götte


Stroke prevention II

CHAIRS: Helmut Pürerfellner und Thorsten Lewalter

  • Refining stroke risk | Jonas Oldgren, Uppsala, SE
  • Periinterventional anticoagulation and antidotes |                                                                   Jan Steffel, Zurich, CH
  • Anticoagulation in patients after a bleeding event | Gregory Lip, Liverpool, UK
  • Future opportunities in EU Funding – Horizon Europe |                                                           Grzegorz Owsianik, Brussels, BE


Summary of the plenary sessions (Hein Heidbüchel):



  1. Biomarkers for AF – diagnosis, prognostication, stratified therapy
  2. How can changes in atrial tissue characteristics advance the concept of atrial cardiomyopathy and ultimately inform patient management?
  3. Treatment of underlying conditions and life style changes – value for prevention of AF and for management of patients with AF
  4. When to initiate anticoagulation: Do we need dynamic risk factors (age, blood pressure, AF burden / AHRE)?
  5. What to do when anticoagulation fails / difficult decisions in anticoagulation
  6. Developing better rhythm control therapy – patient pathways, combination therapy, therapy selection, monitoring of success
  7. AF and heart failure – what to do?
  8. Access to therapy and quality of care



The conference was co-financed by AFNET and EHRA and received additional financial support from CATCH ME (grant agreement No 633196), which is funded by the European Union’s Horizon 2020 research and innovation programme.